Company
Headquarters: Parsippany, NJ, United States
Employees: 2,200
CEO: Mr. Devdatt Kurdikar
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $1.12 B |
| EBITDA | $207.6 M |
| Gross Profit TTM | $749.9 M |
| Profit Margin | 4.93% |
| Operating Margin | 25.93% |
| Quarterly Revenue Growth | 0.60% |
Embecta Corp. has the following listings and related stock indices.
Stock: NASDAQ: EMBC